ArticleAnnals of Indian Academy of Neurology
Propranolol: A 50-Year Historical Perspective.
Article in Annals of Indian Academy of Neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Overcoming the impact of physiologic tremors in ophthalmology.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Pooled it
- A single-center clinical trial evaluating topical propranolol for preventing stress-induced hair loss.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Trial
- Article
- Psychological Scars and Physical Consequences: Linking PTSD to Cardiovascular Health.Journal of cardiovascular translational research · 2026Review
- Extended Sustained Release of Propranolol Hydrochloride from Siloxane-Poly(propylene Oxide) Hybrid Material: A Multistep Mechanism.ACS omega · 2026Article
- Beta Blocker Intoxications in Belgium: A Data Analysis with Focus on Propranolol.Pharmacy (Basel, Switzerland) · 2026Article
- A chitosan-based thermosensitive hydrogel incorporating propranolol nanoparticles to promote early osseointegration and peri-implant soft-tissue healing.RSC advances · 2026Article
- Sex as a biological variable and pre-specified sub-subgroup analyses: what would Sir James Black and Sir Richard Peto say?European heart journal · 2026Article
- Article
- Article
- Drug-Induced Glucose Metabolism Disorders: Role of Aryl Hydrocarbon Receptor.Journal of xenobiotics · 2025Review
- Systemic administration of analgesic buprenorphine, but not carprofen, affects cardiomyocyte contractility in rodents.Journal of molecular and cellular cardiology plus · 2025Article
- Pharmaceutical compounds in marine ecosystems: ecotoxicological effects and risk assessment in phytoplankton and zooplankton.Ecotoxicology (London, England) · 2025Article
- Structural and Pharmacological Insights into Propranolol: An Integrated Crystallographic Perspective.International journal of molecular sciences · 2025Review
- Enantiocomplementary Bioreduction of Flexible Ring N-(3-Oxobutyl)Heterocycles Providing Enantiopure Chiral Fragments for Drug Discovery.Chembiochem : a European journal of chemical biology · 2025Article
- Stress regulatory hormones and cancer: the contribution of epinephrine and cancer therapeutic value of beta blockers.Endocrine · 2025Review
- Principles and Design of Molecular Tools for Sensing and Perturbing Cell Surface Receptor Activity.Chemical reviews · 2025Review
- From heart to brain: cognitive potential of propranolol and diltiazem through cholinergic enhancement via butyrylcholinesterase inhibition.Frontiers in pharmacology · 2025Article
- Adrenergic signaling during parasitic infections.Frontiers in immunology · 2025Review
- Inappropriate use of propranolol among medical and dental students at the University of Jordan: cross-sectional study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Propranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago. It was not long before several other cardiovascular as well as noncardiovascular therapeutic uses of propranolol were discovered. Propranolol soon became a powerful tool for physicians in the treatment of numerous conditions such as hypertension, cardiac arrhythmias, myocardial infarction, migraine, portal hypertension, anxiety, essential tremors, hyperthyroidism, and pheochromocytoma. Owing to its action at multiple receptor sites, propranolol exerts several central and peripheral effects and is therefore useful in various conditions. Right from reduction in postmyocardial mortality to control of anxiety in performers, propranolol plays an important role in a plethora of medical conditions. Interestingly, even today, newer indications of this age-old drug are being discovered. Moreover, propranolol treatment has been found to be cost-effective when compared to other corresponding treatment options for individual indications. In this article, we attempt to recount the journey of propranolol right from its inception to the present day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.